IN VITRO ANTIMICROBIAL ACTIVITY EVALUATION FOR DIFFERENT PHARMACEUTICAL DOSAGE FORMS OF CIPROFLOXACIN IN ADEN-YEMEN

Ciprofloxacin (CIP) is classified as a second-generation fluoroquinolone structurally similar to nalidixic acid. It is a widely used antibiotic to treat different types of bacterial infections. The present study was carried out to evaluate the antimicrobial activity of three different dosage forms of CIP [tablets (Tab coded I, II, III), CIP infusion (Infusion coded I, II, III) and CIP eye drop (Eyedrop coded I, II, III)]. Three most commonly prescribed and dispensed brands for each dosage form were selected. All studied brands were within their shelf life. All brands examined by spectroscopy and the quantity of the active ingredients was with the permitted limits of British pharmacopeia (95-105%). The disk diffusion method was used to evaluate the antimicrobial activity of CIP against E. coli and Staphylococcus Aureus. The highest inhibition zone was at low concentration against E. coli, by Tab-II, Tab-I, and Tab-III tablets respectively. While in the case of infusion, the Infusion-III showed the highest inhibition zone, followed by Infusion-I and Infusion-II. In the case of Staphylococcus Aureus, all Tab I, II, and III have similar potency. At low concentration, Infusion II, III indicated similar while Infusion I had lower potency. However, all brands had slightly higher potency over the standard. All brands of eye drops showed nearly similar potencies against Staphylococcus Aureus with a slight superiority of Eyedrop-I over Eyedrop-II then Eyedrop-III in the highest concentration. All the brands of eye drops showed antimicrobial activity slightly lower than standard. Post-marketing surveillance is an essential issue to distinguish poor-quality medicines. The current study revealed that the marketed CIP pharmaceutical dosage forms showed reasonable antimicrobial activity except for the eyedrops dosage forms which showed slightly lower inhibition zone in comparison to standard.